Hologic, Third Wave deal
Hologic will acquire fellow diagnostics company Third Wave for $11.25 per share, or about $580 million in cash. The price is a 7% premium to Third Wave’s close of $10.50 on June 6, the last trading day before the deal was announced. Hologic said the deal will broaden its product offerings in diagnostics for women. Third Wave develops and markets molecular diagnostic reagents for DNA and RNA analysis applications based on its Invader chemistry. It submitted PMAs in April for two HPV tests, for which it hopes to receive FDA approval in 1H09. Cervista HR, a 14-type high-risk HPV test, and Cervista 16/18, a 16/18 genotyping HPV test, both have CE Mark approval in the EU. The company markets diagnostics for cystic fibrosis (CF), HCV and cardiovascular risk.
Hologic markets the ThinPrep pap test, as well as imaging diagnostics for women’s health including Selenia Full Field digital mammography and QDR Series bone densitometer for bone density assessment. ...